{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 16 of 129', 'IGA', \"Investigator's Global Assessment\", 'IgE', 'immunoglobulin E', 'IgG4', 'immunoglobulin G4', 'IL', 'interleukin', 'IMP', 'investigational medicinal product', 'IRB', 'institutional review board', 'IWRS', 'interactive web response system', 'LEO', 'LEO Pharma A/S', 'LOCF', 'last observation carried forward', 'PK', 'pharmacokinetics', 'nAB', 'neutralising antibodies', 'NIMP', 'non-investigational medicinal product', 'NRS', 'numeric rating scale', 'PGI-B', 'Patient Global Impression of Bother', 'PGI-S', 'Patient Global Impression of Severity', 'POEM', 'Patient Oriented Eczema Measure', 'PRO', 'patient-reported outcome', 'Q2W', 'every 2 weeks', 'Q4W', 'every 4 weeks', 'SAE', 'serious adverse event', 'SC', 'subcutaneous', 'SCORAD', 'Scoring Atopic Dermatitis', 'SCORAD50', 'at least 50% reduction in SCORAD score', 'SCORAD75', 'at least 75% reduction in SCORAD score', 'TCI', 'topical calcineurin inhibitor(s)', 'TCS', 'topical corticosteroid(s)', 'Th2', 'T-helper-2', 'ULN', 'upper limit of normal (range)', 'UV', 'ultraviolet', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 17 of 129', '1 Protocol synopsis', 'Trial ID', 'LP0162-1339', 'EudraCT no.', '2017-002065-21', 'NCT no.', '03363854', 'Title of trial', 'ECZTRA 3 (ECZema TRAlokinumab trial no. 3)', 'A randomised, double-blind, placebo-controlled, phase 3 trial to evaluate the', 'efficacy and safety of tralokinumab in combination with topical corticosteroids', '(TCS) in subjects with moderate-to-severe atopic dermatitis (AD) who are', 'candidates for systemic therapy.', 'Short title', 'Tralokinumab in combination with TCS for moderate-to-severe AD.', 'Main objectives', 'Primary objective:', 'To demonstrate that tralokinumab in combination with TCS is superior to', 'placebo in combination with TCS in treating moderate-to-severe AD.', 'Secondary objectives:', 'To evaluate the efficacy of tralokinumab in combination with TCS on severity', 'and extent of AD, itch, and health-related quality of life compared with placebo', 'in combination with TCS.', 'To assess safety of tralokinumab in combination with TCS when used to treat', 'moderate-to-severe AD for 32 weeks.', 'Primary endpoints', \"Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost\", 'clear) at Week 16.', 'At least 75% reduction in Eczema Area and Severity Index (EASI)', 'score from baseline (EASI75) at Week 16.', 'Secondary', 'Change in Scoring Atopic Dermatitis (SCORAD) from baseline to', 'endpoints', 'Week 16.', 'Reduction of Worst Daily Pruritus numeric rating scale (NRS) (weekly', 'average) of at least 4 from baseline to Week 16.', 'Change in Dermatology Life Quality Index (DLQI) from baseline to', 'Week 16.', 'Trial design', 'The trial will consist of a screening period of 2 to 6 weeks (Weeks -6/-2 to 0),', 'an initial treatment period of 16 weeks (Weeks 0 to 16), a continuation', 'treatment period of 16 weeks (Weeks 16 to 32), and a 14-week off-treatment', 'follow-up period for the assessment of safety (Weeks 32 to 46).', 'Subjects will be randomised in a 2:1 ratio to receive multiple subcutaneous', '(SC) doses of tralokinumab (300 mg) or placebo every 2 weeks (Q2W)', 'following a loading dose of 600 mg on Day 0 (or 4 mL placebo).', 'Randomisation will be stratified by region and baseline disease severity.', 'At Week 16, subjects will continue into continuation treatment until Week 32', '(the last dose of investigational medicinal product [IMP] will be given at', 'Week 30). The treatment during the continuation treatment period will depend', \"on the regimen received in the initial treatment period and on the subject's\", 'clinical response at Week 16 (defined as IGA of 0 or 1 on a 5-point scale', 'ranging from 0 [clear] to 4 [severe], or EASI75).', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}